gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Bruton agammaglobulinemia tyrosine kinase

Btk, XLA, Bruton's tyrosine kinase, Xid
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. [provided by RefSeq, Nov 2008] (from NCBI)
Top mentioned proteins: BCR, CAN, Syk, V1a, Tec
Papers using Btk antibodies
Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors
Supplier
von Lindern Marieke et al., In The Journal of Experimental Medicine, 1997
... Rabbit antisera recognizing the mouse EpoR, PLCγ1, Btk, c-Kit, and the antiphosphotyrosine mouse monoclonal antibody PY99 were obtained from Santa Cruz Biotechnology, Inc ...
Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ
Supplier
Nürnberg Bernd et al., In The Journal of Cell Biology, 1997
... and BtkPH, restriction sites were introduced by PCR using the indicated primers, the Advantage™ II PCR enzyme system (CLONTECH Laboratories, Inc.) and the ...
The A and the extended V N-terminal regions of streptococcal protein I/IIf mediate the production of tumour necrosis factor alpha in the monocyte cell line THP-1.
Supplier
El Khoury Joseph, In PLoS ONE, 1997
... Anti-Btk mouse IgG monoclonal antibodies were from BD Transduction Laboratories (Le Pont de Claix, France) and anti-TNF-α mouse monoclonal antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany) ...
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Supplier
Nukiwa Toshihiro et al., In Respiratory Research, 1993
... Briefly, mononuclear cells were surface stained with phycoerythrin-labeled anti-CD14 antibody, then fixed, permealized, incubated with anti-BTK monoclonal antibody 48-2H [5] or control IgG1 (Dako, Kyoto, Japan), and then ...
Papers on Btk
REQUIREMENT OF THE TEC FAMILY TYROSINE KINASE BTK29A FOR COURTSHIP MEMORY IN Drosophila MALES.
New
Yamamoto et al., Sendai, Japan. In Arch Insect Biochem Physiol, Feb 2016
The Btk29A(ficP) mutant males null for the Btk29A type 2 isoform, a fly homolog of the nonreceptor tyrosine kinase Btk, show no courtship suppression, while Btk29A hypomorphic males exhibit a rapid decline in courtship suppression, leading to its complete loss within 30 min.
Ikaros limits follicular B cell activation by deregulating B cell receptor signaling pathways.
New
Kastner et al., Illkirch-Graffenstaden, France. In Biochem Biophys Res Commun, Feb 2016
Unstimulated mutant B cells show deregulation of positive and negative regulators of signal transduction at the mRNA level, and constitutive phosphorylation of ERK, p38, SYK, BTK, AKT and LYN.
Ibrutinib for mantle cell lymphoma.
New
Rule et al., Plymouth, United Kingdom. In Future Oncol, Feb 2016
Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor.
Mantle Cell Lymphoma.
Review
New
Impact
Wang et al., Australia. In J Clin Oncol, Feb 2016
In particular, agents recently approved by the Food and Drug Administration include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton's tyrosine kinase inhibitor ibrutinib.
The Neutrophil Btk Signalosome Regulates Integrin Activation during Sterile Inflammation.
New
Impact
Zarbock et al., Münster, Germany. In Immunity, Feb 2016
We demonstrated that the Bruton's tyrosine kinase (Btk) was required for multiple Mac-1 activation events involved in neutrophil recruitment and functions during sterile inflammation triggered by fMLF.
Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
New
Tun et al., Jacksonville, United States. In Rare Tumors, Jan 2016
Cutaneous and systemic relapses responded well to immunomodulatory therapy with lenalidomide followed by Bruton's tyrosine kinase inhibition with ibrutinib.
Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Review
New
O'Brien et al., Houston, United States. In Blood Rev, Jan 2016
These include B-cell receptor (BCR) inhibitors such as Bruton tyrosine kinase (BTK) inhibitors, PI3 kinase inhibitors, and Syk inhibitors, novel anti-CD20 monoclonal antibodies such as ofatumumab and obinutuzumab, and Bcl-2 antagonists such as venetoclax (ABT-199).
Chronic lymphocytic leukemia (CLL) - Then and Now.
Review
New
Jain et al., Houston, United States. In Am J Hematol, Jan 2016
In therapy, the field of CLL has seen major changes from oral chlorambucil and steroids prior to 1980s, to chemo-immunotherapy (CIT) with fludarabine, cyclophosphamide, rituximab (FCR) to the orally administered targeted therapeutic agents inhibiting kinases in the B cell receptor (BCR) signaling pathway such as Ibrutinib (BTK inhibitor) and Idelalisib (p110 PI3Kδ inhibitor) and novel anti-CD20 mAb's (monoclonal antibodies) such as obinutuzumab.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
New
Impact
Furman et al., Orange, Australia. In N Engl J Med, Jan 2016
UNASSIGNED: Background Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
New
Impact
HELIOS investigators et al., Jacksonville, United States. In Lancet Oncol, Jan 2016
We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.
New
Zhang et al., Tianjin, China. In Oncol Lett, Dec 2015
These inhibitors include spleen tyrosine kinase, mammalian target of rapamycin, phosphoinositide 3'-kinase and Bruton's tyrosine kinase (BTK).
Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
New
Woo Lee et al., Chinju, South Korea. In Plos One, Dec 2015
Bruton's tyrosine kinase (BTK) is a cytoplasmic, non-receptor tyrosine kinase which is expressed in most of the hematopoietic cells and plays an important role in many cellular signaling pathways.
Covalent targeting of acquired cysteines in cancer.
Review
New
Dansen et al., Utrecht, Netherlands. In Curr Opin Chem Biol, Dec 2015
For example, targeting cysteine residues in the ATP-binding pockets of kinases with thiol-reactive molecules has afforded increased selectivity and potency to drugs like imbrutinib, which inhibits the oncogene BTK, and CO-1686 and AZD9291 that target oncogenic mutant EGFR.
Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
Review
New
Jaiyesimi et al., Royal Oak, United States. In Clin Lymphoma Myeloma Leuk, Dec 2015
Considerable research attention has focused on the Bruton tyrosine kinase (BTK) as a potential therapeutic target in B-cell malignancies.
Ibrutinib in previously treated Waldenström's macroglobulinemia.
New
Impact
Advani et al., United States. In N Engl J Med, May 2015
MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.
Tyrosine kinase Btk is required for NK cell activation.
GeneRIF
Cao et al., Shanghai, China. In J Biol Chem, 2012
Data suggest a role of tyrosine kinase Btk in the regulation of immune cell unctions and innate inflammatory response.
Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).
GeneRIF
Nore et al., Huddinge, Sweden. In Mol Cell Biol, 2012
mapped the interaction site to the C terminus of the Btk SH3 domain
Single-chain variable fragment intrabody impairs LPS-induced inflammatory responses by interfering with the interaction between the WASP N-terminal domain and Btk in macrophages.
GeneRIF
Kitani et al., Tsukuba, Japan. In Biochem Biophys Res Commun, 2012
These observations strongly suggest that the phosphorylation of WASP by Btk plays a pivotal role in transducing the LPS signaling pathway in macrophages.
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.
GeneRIF
Hendriks et al., Rotterdam, Netherlands. In Blood, 2012
Transgenic mice overexpressing Btk specifically in B cells spontaneously formed germinal centers and manifested increased plasma cell numbers, leading to antinuclear autoantibody production and systemic lupus erythematosus (SLE)-like autoimmune pathology.
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
GeneRIF
Lam et al., Singapore, Singapore. In Proc Natl Acad Sci U S A, 2012
BTK plays a critical role in initiating TLR3 signaling.
share on facebooktweetadd +1mail to friends